Social capital at work How family, friends and civic ties relate to labour market outcomes

This paper investigates the extent to which an individual's 'stock' of social capital relates to labour force outcomes, over and above more well established determinants. In particular, it examines how family and kinship networks, friends and neighbours relate to individual labour market outcomes, compared with the role of civic ties and institutional networks. Using data collected from a national random sample of 1500 Australians, the paper investigates the relative impact of trust, bonding, bridging and linking relationships upon labour force status and successful job search method.

In situ determination of strength and stiffness of structural lumber and composite products

Wood is prone to deterioration that reduces its load bearing capabilities. Periodically, older wooden members need to be inspected to ensure the strength and stability of the structure. Historically these inspection methods have consisted of visual inspections lacking scientific basis.;Non-destructive testing (NDT) methods were investigated by this research for the possibility of evaluating modulus of rupture and modulus of elasticity of built-in wooden members. Methods included stress wave timing for dynamic MOE determination and screw withdrawal force (SWF) for MOR and density prediction. Standard ASTM testing procedures were used to determine the actual properties and statistical relationships between these variables identified. Using the developed relationships, simple prediction models were developed to estimate actual properties.;Results of this investigation revealed that stress wave timing is a reliable predictor of the actual MOE of the material. Investigation results also indicated that SWF is a reliable indicator of both density and MOR

Properties of Wood/recycled Textile Composite Panels

This study evaluated the potential to use recycled cotton textiles as filler and possibly reinforcement in the core of oriented strandboard (OSB) panels. Nominal 11.1-mm-thick, 686 x 686-mm OSB/textile fiber composite panels (50% surface and 50% core layers) were fabricated. Recycled textile material (0, 5, 15, 25, and 50% of the total weight percentage in the panel) was blended with mixed hardwood core strands. For each combination of wood and textile material, 10 panels were produced for a total of 50 panels. Internal bond strength, static bending strength and stiffness, water absorption, thickness swell, and nail withdrawal strength properties were evaluated. The major finding of the study indicated that compared with controls (ie panels with 0% textile material), panels with 5% recycled textiles did not have a statistically significant difference in bending strength (modulus of rupture) and elasticity (modulus of elasticity) or nail withdrawal strength. Additionally, although the controls had the greatest average thickness swell, none of the groups tested showed a statistically significant difference (p = 0.064). The study indicated that there is potential for adding 5% recycled textiles to the core of OSB panels without significantly decreasing physical or mechanical properties

Adapting a number sense task to learn more about K-5 student reasoning

Look deeper into how 5th grade students think through a task by examining standards from earlier grades

Advancing the pathologic phenotype of giant axonal neuropathy: early involvement of the ocular lens

Abstract Giant axonal neuropathy (GAN; ORPHA: 643; OMIM# 256850) is a rare, hereditary, pediatric neurodegenerative disorder associated with intracellular accumulations of intermediate filaments (IFs). GAN knockout (KO) mouse models mirror the IF dysregulation and widespread nervous system pathology seen in human GAN. Validation of therapeutic efficacy and viral vector delivery systems with these GAN KO models has provided the springboard for the development of a viral vector being delivered intrathecally in an ongoing Phase I gene therapy clinical trial for the treatment of children with GAN ( https://clinicaltrials.gov/ct2/show/NCT02362438 ). During the course of a comprehensive pathologic characterization of the GAN KO mouse, we discovered the very early and unexpected involvement of the ocular lens. Light microscopy revealed the presence of intracytoplasmic inclusion bodies within lens epithelial cells. The inclusion bodies showed strong immunohistochemical positivity for glial fibrillary acidic protein (GFAP). We confirmed that intracytoplasmic inclusion bodies are also present within lens epithelial cells in human GAN. These IF inclusion bodies in lens epithelial cells are unique to GAN. Similar IF inclusion bodies in lens epithelial cells have not been reported previously in experimental animal models or human diseases. Since current paradigms in drug discovery and drug repurposing for IF-associated disorders are often hindered by lack of validated targets, our findings suggest that lens epithelial cells in the GAN KO mouse may provide a potential target, in vivo and in vitro, for evaluating drug efficacy and alternative therapeutic approaches in promoting the clearance of IF inclusions in GAN and other diseases characterized by intracellular IF accumulations

Folate Status of Reproductive Age Women and Neural Tube Defect Risk: The Effect of Long-Term Folic Acid Supplementation at Doses of 140 µg and 400 µg per Day

Primary prevention of most folate-responsive neural tube defects (NTDs) may not require 400 μg folic acid/day but may be achieved by attaining a high maternal folate status. Using RBC folate ≥906 nmol/L as a marker for NTD risk reduction, the study aimed to determine the change in blood folate concentrations in reproductive age women in response to long-term folic acid supplementation at 400 µg/day and 140 µg/day (dose designed to mimic the average daily folic acid intake received from New Zealand’s proposed mandatory bread fortification program). Participants were randomly assigned to a daily folic acid supplement of 140 µg (n = 49), 400 µg (n = 48) or placebo (n = 47) for 40 weeks. RBC folate concentrations were measured at baseline, and after 6, 12, 29 and 40 weeks. At 40 weeks, the overall prevalence of having a RBC folate <906 nmol/L decreased to 18% and 35% in the 400 µg and 140 µg groups, respectively, while remaining relatively unchanged at 58% in the placebo group. After 40 weeks, there was no evidence of a difference in RBC folate between the two treatment groups (P = 0.340), nor was there evidence of a difference in the odds of a RBC folate <906 nmol/L (P = 0.078). In conclusion, the average daily intake of folic acid received from the proposed fortification program would increase RBC folate concentrations in reproductive age women to levels associated with a low risk of NTDs

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial

Importance Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity. Objective To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. Design, Setting, and Participants Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites. Interventions Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks, followed by a 1-week washout. Main Outcomes and Measures Primary end point was the total maximal chorea score change from baseline (the average of values from the screening and day-0 visits) to maintenance therapy (the average of values from the week 9 and 12 visits) obtained by in-person visits. This study was designed to detect a 2.7-unit treatment difference in scores. The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clinical Global Impression of Change (CGIC), the change in 36-Item Short Form– physical functioning subscale score (SF-36), and the change in the Berg Balance Test. Results Ninety patients with Huntington disease (mean age, 53.7 years; 40 women [44.4%]) were enrolled. In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95% CI, 11.2-12.9) to 7.7 (95% CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95% CI, 12.2-14.3) to 11.3 (95% CI, 10.0-12.5); the mean between-group difference was –2.5 units (95% CI, –3.7 to –1.3) (P < .001). Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002). As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6 (13%) in the placebo group (P = .002). In the deutetrabenazine group, the mean SF-36 physical functioning subscale scores decreased from 47.5 (95% CI, 44.3-50.8) to 47.4 (44.3-50.5), whereas in the placebo group, scores decreased from 43.2 (95% CI, 40.2-46.3) to 39.9 (95% CI, 36.2-43.6), for a treatment benefit of 4.3 (95% CI, 0.4 to 8.3) (P = .03). There was no difference between groups (mean difference of 1.0 unit; 95% CI, –0.3 to 2.3; P = .14), for improvement in the Berg Balance Test, which improved by 2.2 units (95% CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95% CI, 0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia. Conclusions and Relevance Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

The Advisibility of Using A1c as a Screening Method for Early Detection of Type 2 Diabetes Mellitus

Type 2 diabetes in the United States is on the rise. Millions of individuals are asymptomatic yet have undiagnosed diabetes. With daunting numbers of individuals who are obese, inactive, and have other risk factors that contribute to the development of diabetes, it is imperative for practitioners to screen individuals at point of care (POC) in an attempt to diagnose type 2 diabetes as early as possible to assure early management of glycemic control to prevent future complications. Current standards of care recommend using the plasma AIc as one possible test for diagnosing and screening for diabetes in patients with known risk factors, and those over 45 years of age. There is good evidence that the Alc is a reliable test for diagnosing diabetes, and the POC test is as accurate as the laboratory Al c. Studies indicate that individuals may have elevated blood sugars for years before an actual diagnosis of diabetes is known. Research also suggests that this hyperglycemic period can be as long as 7-12 years before symptoms occur, though the exact number of years is unknown. Once symptoms of diabetes have occurred, there are indications that retinopathy, nephropathy, and neuropathy are already underway. Further, studies have shown that lifestyle interventions of weight loss, exercise, diet, and oral anti-diabetic medications can delay or prevent a diagnosis of diabetes. Using the Chronic Care Model as a guiding framework, this paper reviews available literature to determine the advisability of using POC Alc to screen tor type 2 diabetes